Six years after enrolling in a small clinical trial, several patients with pancreatic cancer who received a personalized messenger ribonucleic acid vaccine are still alive, offering new hope against one of the deadliest forms of cancer. The trial followed 16 patients, and seven of the eight who responded to the vaccine remain alive years later, significantly outperforming typical survival expectations.

The vaccine was designed specifically for each patient, training the immune system to recognize and attack unique mutations in their tumors. Donna Gustafson, who joined the study shortly after undergoing surgery in 2020, chose the experimental treatment instead of standard chemotherapy at that time. Her participation came before messenger ribonucleic acid vaccines became widely known during the coronavirus pandemic.

Experts caution that while the results are highly encouraging, the study was small and larger trials are needed to confirm the findings. Still, the long-term survival of these patients suggests that personalized vaccines could become a powerful new tool in treating pancreatic cancer, a disease that has historically had very poor outcomes.